A combination treatment between platinum-containing drugs and a PARP inhibitor is one of the therapeutic strategies to improve their efficacy in BRCA1/2-deficient breast cancer cells [26,64,65,66,67]. This evidence concerns the gene BRCA1 and breast carcinoma.